Amicus Therapeutics Inc. (NASDAQ:FOLD)‘s stock had its “hold” rating restated by investment analysts at Robert W. Baird in a research note issued on Tuesday. They presently have a $7.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $9.00. Robert W. Baird’s target price would suggest a potential upside of 17.06% from the company’s previous close.

Several other equities analysts also recently weighed in on the company. Chardan Capital reissued a “buy” rating and set a $16.00 target price (up previously from $15.00) on shares of Amicus Therapeutics in a research report on Tuesday. Zacks Investment Research downgraded Amicus Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, October 18th. Cowen and Company reissued an “outperform” rating and set a $15.00 target price on shares of Amicus Therapeutics in a research report on Tuesday, November 8th. Finally, Leerink Swann reissued a “buy” rating and set a $17.00 target price on shares of Amicus Therapeutics in a research report on Tuesday, November 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. Amicus Therapeutics currently has an average rating of “Buy” and a consensus target price of $11.08.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics (NASDAQ:FOLD) opened at 5.98 on Tuesday. Amicus Therapeutics has a 12 month low of $4.98 and a 12 month high of $11.58. The stock’s market cap is $851.11 million. The firm’s 50-day moving average price is $7.82 and its 200 day moving average price is $6.97.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.01. The firm had revenue of $2.10 million for the quarter, compared to analysts’ expectations of $1.71 million. On average, analysts anticipate that Amicus Therapeutics will post ($1.38) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was posted by Financial Market News and is the propert of of Financial Market News. If you are accessing this report on another domain, it was stolen and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at http://www.financial-market-news.com/amicus-therapeutics-inc-fold-rating-reiterated-by-robert-w-baird/1212204/.

In other news, insider Hung Do sold 25,000 shares of the stock in a transaction on Tuesday, September 6th. The stock was sold at an average price of $7.00, for a total transaction of $175,000.00. Following the transaction, the insider now owns 583,453 shares of the company’s stock, valued at approximately $4,084,171. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO William D. Baird III sold 20,500 shares of the stock in a transaction on Tuesday, September 20th. The stock was sold at an average price of $8.00, for a total value of $164,000.00. Following the transaction, the chief financial officer now directly owns 56,450 shares in the company, valued at approximately $451,600. The disclosure for this sale can be found here. 3.40% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the company. Prudential Financial Inc. increased its position in Amicus Therapeutics by 52.6% in the second quarter. Prudential Financial Inc. now owns 937,580 shares of the biopharmaceutical company’s stock worth $5,119,000 after buying an additional 323,280 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Amicus Therapeutics by 3,392.6% in the second quarter. Dimensional Fund Advisors LP now owns 435,736 shares of the biopharmaceutical company’s stock worth $2,379,000 after buying an additional 423,260 shares during the last quarter. SECOR Capital Advisors LP purchased a new position in Amicus Therapeutics during the second quarter worth about $414,000. Nationwide Fund Advisors increased its position in Amicus Therapeutics by 8.5% in the second quarter. Nationwide Fund Advisors now owns 112,325 shares of the biopharmaceutical company’s stock worth $613,000 after buying an additional 8,756 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System increased its position in Amicus Therapeutics by 36.6% in the second quarter. State Board of Administration of Florida Retirement System now owns 55,248 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 14,810 shares during the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

5 Day Chart for NASDAQ:FOLD

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.